{
    "clinical_study": {
        "@rank": "16495", 
        "arm_group": [
            {
                "arm_group_label": "Stage IV CRC"
            }, 
            {
                "arm_group_label": "Stage IV NSCLC"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      Correlation of the skin and/or eye toxicity grade secondary to Cetuximab or Panitumumab and\n      the SNP profile of the Epidermal Growth Factor Receptor (EGFR) domain III region.\n\n      Secondary Objectives:\n\n      Correlation of SNP profile with indicators of tumour response parameters, such as\n      radiological response, duration of response, time to progression (TTP), overall survival\n      (OS) time, incidence of non-dermatological adverse events."
        }, 
        "brief_title": "Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4", 
        "condition": [
            "Colorectal Cancer", 
            "Non-Small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Colorectal Neoplasms", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Baseline assessment:\n\n        -  Contact Lenses\n\n        -  Medical History\n\n        -  Previous chemotherapy\n\n        -  Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)\n\n        -  Symptom Assessment (Pre-existing skin and/or eye conditions, CEA measurement (CRC\n           only), Disease status (TNM Staging))\n\n        -  Planned chemotherapy regimen\n\n        -  Radiotherapy\n\n      Blood Sample: A 2ml blood sample should be collected in ethylenediamine-tetraacetic acid\n      (EDTA) containing Vacutainer at any time before or after starting treatment. DNA will be\n      extracted from the samples and the 11 SNPs in the region of the EGFR gene encoding domain\n      III will be characterized.\n\n      Follow-up Assessment: with every second cycle of Cetuximab- or Panitumumab-containing\n      regimen (CRC: every 2. Week; NSCLC: every 3-4 weeks):\n\n        -  Visit Number and Date\n\n        -  Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)\n\n        -  Symptom Assessment (CEA measurement (CRC only), Disease status (TMN Staging), Skin\n           Toxicity (CTCAE) grading)\n\n        -  Current chemotherapy regimen\n\n        -  Radiotherapy\n\n        -  CEA measurement only for CRC (every second cycle/every 4 weeks)\n\n      Long-term follow-up (up to 5 years):\n\n        -  CT restaging (TNM Staging) should be done 3 monthly for as long as the subject is\n           receiving Cetuximab- or Panitumumab- containing regimen or if there is suspicion of\n           disease progression.\n\n        -  OS"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Stage IV (AJCC 7th Edition TMN Staging, Appendix C), histologically confirmed CRC\n             with wild-type KRAS and not a candidate for metastasectomy.\n\n          2. Stage IV (AJCC 7th Edition, TMN Staging, Appendix C) NSCLC expressing EGFR (IHC\n             tested)\n\n          3. Patients, who will receive treatment with an EGFR-antibody (Cetuximab or\n             Panitumumab).\n\n          4. Karnofsky performance status (Appendix B) score \u226560.\n\n          5. Acceptable laboratory values:\n\n               -  Haemoglobin \u2265 9 g/dL.\n\n               -  Neutrophil count \u2265 1.0 x 10^9/L.\n\n               -  Platelet count \u2265100 x 10^9/L.\n\n               -  Serum creatinine \u22641.5 times the upper limit of normal.\n\n               -  Bilirubin \u22641.5 times the upper limit of normal.\n\n               -  Aspartate aminotransferase and alanine aminotransferase \u22645 times the upper limit\n                  of normal.\n\n        Exclusion Criteria:\n\n          1. Aged < 18 years\n\n          2. Prior exposure to Cetuximab or Panitumumab\n\n          3. The CRC does not carry wild-type KRAS.\n\n          4. The NSCLC stains negative for EGFR protein expression\n\n          5. Second cancer diagnosis (apart from non-melanoma skin cancer)\n\n          6. Known hypersensitivity to Cetuximab or Panitumumab, or murine protein.\n\n          7. Known history of coronary artery disease, arrhythmias, or congestive heart failure\n             (If the treating physician feels that a patient's coronary artery disease /\n             arrhythmia / congestive heart failure does not place him/her at risk from treatment\n             with an anti-EGFR antibody, the person can be included. This is a clinical decision,\n             which has to be made by the treating physician).\n\n          8. Known to be pregnant (pregnancy test is not mandatory) or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patient Population:\n\n        150 Patients with histologically proven stage IV (AJCC 7th Edition) colorectal cancer\n        (CRC) expressing wild-type KRAS or stage IV non-small cell lung cancer (NSCLC) expressing\n        EGFR (tested by immunohistochemistry (IHC)), with no previous exposure to Cetuximab or\n        Panitumumab, who will receive treatment with an EGFR-antibody (Cetuximab or Panitumumab)."
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01726309", 
            "org_study_id": "ICORG 08-40"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "074-9123798"
                }, 
                "facility": {
                    "address": {
                        "city": "Letterkenny", 
                        "country": "Ireland", 
                        "state": "Donegal"
                    }, 
                    "name": "Letterkenny General Hospital"
                }, 
                "investigator": {
                    "last_name": "Karen Duffy, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact person", 
                    "phone": "021-4542807"
                }, 
                "facility": {
                    "address": {
                        "city": "Cork", 
                        "country": "Ireland"
                    }, 
                    "name": "Bon Secours Hospital"
                }, 
                "investigator": {
                    "last_name": "Brian Bird, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact person", 
                    "phone": "021-4546400"
                }, 
                "facility": {
                    "address": {
                        "city": "Cork", 
                        "country": "Ireland"
                    }, 
                    "name": "Cork University Hospital"
                }, 
                "investigator": {
                    "last_name": "Seamus O'Reilly, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "(01) 414 2000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "The Adelaide & Meath Hosptal, Dublin Incorporating The National Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Ray McDermott, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "01-8093000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "Beaumont Hospital"
                }, 
                "investigator": {
                    "last_name": "Liam Grogan, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "01-4142012"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland", 
                        "zip": "4"
                    }, 
                    "name": "St Vincent's University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ray McDermott, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "01-8545075"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland", 
                        "zip": "7"
                    }, 
                    "name": "Mater Misericordiae University Hospital"
                }, 
                "investigator": {
                    "last_name": "David Gallagher, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact person", 
                    "phone": "091-524222"
                }, 
                "facility": {
                    "address": {
                        "city": "Galway", 
                        "country": "Ireland"
                    }, 
                    "name": "Galway University Hospital"
                }, 
                "investigator": {
                    "last_name": "Gregory Leonard, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "(041) 9837601"
                }, 
                "facility": {
                    "address": {
                        "city": "Louth", 
                        "country": "Ireland"
                    }, 
                    "name": "Our Lady of Lourdes Hospital, Drogheda"
                }, 
                "investigator": {
                    "last_name": "Bryan Hennessy, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "051-848000"
                }, 
                "facility": {
                    "address": {
                        "city": "Waterford", 
                        "country": "Ireland"
                    }, 
                    "name": "Waterford Regional Hospital"
                }, 
                "investigator": {
                    "last_name": "Anne Horgan, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_groups": "2", 
        "official_title": "Correlation of Single Nucleotide Polymorphism (SNP) Profile of Domain III of EGFR to Skin and/or Eye Toxicity and Disease Response to Treatment With Cetuximab or Panitumumab - SNP and Cetuximab or Panitumumab Response", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ireland: Health Information and Quality Authority"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Using Common Terminology Criteria for Adverse Events (CTCAE) version 4", 
            "measure": "Correlation between the type and degree of reported skin and/or eye reaction and the SNP profile of the EGFR domain III region.", 
            "safety_issue": "Yes", 
            "time_frame": "Throughout treatment with up to 5 years in follow up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01726309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Time to progression TTP and OS over 5 years", 
            "measure": "Correlation between the SNP profile(s) and disease response", 
            "safety_issue": "No", 
            "time_frame": "Throughout treatment with up to 5 years in follow up"
        }, 
        "source": "ICORG- All Ireland Cooperative Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ICORG- All Ireland Cooperative Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}